Member Info for Propinquity

Here you go, folks, the latest Vox interview: https://audioboom.com/posts/6267228-863-amryt-pharma-amyt-union-jack-oil-ujo-and-malcy-on-savp-sdx-pmo-rkh-eme

Here you go: https://audioboom.com/posts/6139262-nic-charts-today-are-alba-minerals-alba-amryt-pharma-amyt-strategic-minerals-sml?t=0

Check out AMYT on today's Nic's charts on **********.

Perfect opportunity to steadily increase your holdings.

Excitement will probably start to peer over the parapet later on in Q4 (if not later), as the results from the interim analysis of AP101's trial are expected in Q1 2018 - unless the company releases surprises in between then.

A critical criterion in risk-assessment of any share - the credibility and overall quality of the BoD.

No frequent updates will be released, I am afraid - only the interim trial-results will be published early next year (read the relevant RNS).

Cookie, One of the BoD mentioned last year that a NASDAQ listing would be about 18 months from then.

Shrewdy, Good to hear from you - I thought you had abandoned us.

Can't buy any via Hargreaves Lansdown, at the mo.

A long-term investement this should be viewed as: With Ariana's commencing the production of gold , to be bolstered both by proving up more inventory-adding gold, its value will increase, although perhaps not as quickly as it might have without the various placings - but as stoical investors who have seen the lows over the years, a year or two longer more should be relatively painless, to witness the share-enhancing revenue; after all, this gem is more a long-term investment - and lest we forget, the year-low was 1.15, and the year-high was 2.23. But, the next ascent may well be more akin to a ride on a Stannah stairlift instead of on a NASA rocket - with the former a preferable experience to Elon Musk's Falcon 9 (a blow-up): you know you will still reach your destination.

Its interim results will probably be released early next year; they will be a significant indicator of the likelihood of its success.

Mark Sumeray, our Chief Medical Officer, discusses EASE.

Research-note from last year, yet still relevant - hTTps://www.shardcapitalstockbrokers.com/news/747-shard-capital-initiate-coverage-amryt-pharma-plc The table on page 11 compares AMYT's valuation with that of its peers who possess products at similar stages - but, because its products are at phase II/III, then a truer comparison maybe with only two of those: Sage Therapeutics, with products in phase III, valued at £839m; and Ultragenyx, with products in phase II/III, valued at £1.99bn. The conclusion from just those comparisons may indicate an unfair undervaluation of AMYT, at about £50m; even if it reaches a market-cap of £250m, that will be a considerable increase - and, still grossly undervalued compared with its peers, particularly if its products are approved for medical use.

Thinice, A fair counterpoint; but, as you touched on, it's an enviable BoD, populated by successful business-people - not many, if any, other AIM companies can claim that level of qualified expertise and success - allied with Cathal's investing what seems to be his life-savings in this new company, proclaiming a confidence in a markedly different, and sought-after, sector from our previous incarnation's.

Intriguingly, in the second Youtube video of that post, about fourteen minutes in, Catha declares that he would be surprised if AMYT still existed as a company in eighteen months - confident of takeover, then, what with the drugs' pipeline bursting with products, trials, and approvals.

Pleased to see you two have agreed on an entente cordiale.

LOL! The waggish definintion.

Anyone any idea what a rating of 'House Stock' means?

Shrewdy, Always knew you were a broad-minded individual in your outlook on investments.